+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Global Market Report 2024

  • PDF Icon

    Report

  • 175 Pages
  • February 2024
  • Region: Global
  • The Business Research Company
  • ID: 5934006
The cyclin-dependent kinase (cdk) 4/6 inhibitor drugs market size has grown exponentially in recent years. It will grow from $10.18 billion in 2023 to $12.35 billion in 2024 at a compound annual growth rate (CAGR) of 21.3%. The growth observed in the historic period can be attributed to several factors, including the increasing incidence of cancer, clinical success stories showcasing the efficacy of CDK 4/6 inhibitors, a growing aging population, and heightened awareness leading to early diagnosis. These factors collectively contributed to the historical expansion of the use of CDK 4/6 inhibitor drugs in breast cancer treatment.

The cyclin-dependent kinase (cdk) 4/6 inhibitor drugs market size is expected to see rapid growth in the next few years. It will grow to $25.17 billion in 2028 at a compound annual growth rate (CAGR) of 19.5%. The anticipated growth in the forecast period can be attributed to various factors, including the expansion of indications for CDK 4/6 inhibitors, the emergence of new pipeline molecules, the impact of market competition and pricing dynamics, the adoption of personalized medicine approaches, and improvements in global healthcare infrastructure. Major trends expected in the forecast period include advancements in biomarker identification, the rise of oral CDK 4/6 inhibitors, the exploration of CDK 4/6 inhibitors in other cancer types, efforts focused on overcoming resistance mechanisms, and an increase in clinical trials exploring novel CDK 4/6 inhibitors.

The anticipated increase in the prevalence of breast cancer is poised to drive the growth of the cyclin-dependent kinase (CDK) 4/6 inhibitor drug market. Breast cancer, originating in breast cells, prompts the demand for targeted therapies such as CDK4/6 inhibitors, addressing specific types of breast cancer and contributing to managing the escalating prevalence of the disease. As reported by the American Cancer Society in January 2023, breast cancer cases surged from 284,200 in 2021 to 300,590 in 2023, marking a significant increase of 5.76%. Consequently, the rising prevalence of breast cancer is forecasted to be a pivotal driver propelling growth within the cyclin-dependent kinase (CDK) 4/6 inhibitor drug market.

The augmented investment in research and development endeavors for breast cancer treatment is expected to significantly boost the cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market. The increased funding in breast cancer treatment facilitates the innovation and expansion of CDK4/6 inhibitor drugs, enhancing their efficacy and broadening their applications, thereby fostering market expansion. For instance, Susan G. Komen, a reputable US-based breast cancer organization, allocated $21.7 million in June 2022 to sponsor 48 novel research initiatives at 26 esteemed academic medical institutions across the United States. These initiatives aim to enhance patient outcomes, particularly for individuals grappling with aggressive forms of breast cancer or facing recurrence or metastasis. Hence, the amplified investment in research and development for breast cancer treatment emerges as a key factor driving the growth of the cyclin-dependent kinase (CDK) 4/6 inhibitor drug market.

The distinctive array of side effects associated with cyclin-dependent kinase (CDK) 4/6 inhibitor drugs presents a challenge that could potentially impede the market's growth in the forecast period. Among these side effects, neutropenia stands out, marked by a decrease in white blood cells that elevates the risk of infections. This condition is transient and dosage-dependent, typically resolving when the drug dose is adjusted or temporarily halted. According to the National Library of Medicine in June 2023, the most prevalent side effect of CDK 4/6 inhibitors was neutropenia, with rates of occurrence at 80% for palbociclib, 75% for ribociclib, and 41% for abemaciclib. Consequently, the incidence of these side effects poses a hindrance to the growth of the cyclin-dependent kinase (CDK) 4/6 inhibitor drug market.

Major companies operating within the cyclin-dependent kinase (CDK) 4/6 inhibitor drug market are directing their efforts toward the development of advanced therapies, notably combination therapies, aiming to further enhance the treatment landscape for patients, address unmet medical needs, and optimize patient outcomes. Combination therapies involve the simultaneous use of two or more diverse treatment modalities or drugs, aiming to augment the effectiveness of medical interventions. For instance, in October 2021, Eli Lilly and Company, a leading US-based pharmaceutical developer and manufacturer, obtained approval from the U.S. Food and Drug Administration (FDA) for Verzenio (abemaciclib) as the first and sole CDK4/6 inhibitor used in combination with endocrine therapy (such as tamoxifen or an aromatase inhibitor). This combination therapy is intended for the adjuvant treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer (EBC) at a high risk of recurrence and with a Ki-67 score of 20%. This tailored treatment option represents a significant advancement offering improved outcomes for individuals in need of more effective therapeutic approaches.

In July 2022, Pfizer Inc., a renowned US-based pharmaceutical company specializing in CDK4/6 inhibitor drugs, embarked on a collaboration with Arvinas Inc., a prominent biopharmaceutical company also based in the United States. Their joint objective involves the development and commercialization of ARV-471, an investigative oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. This partnership is geared towards addressing the treatment needs of patients coping with locally advanced or metastatic breast cancer. Pfizer Inc. intends to synergize its expertise in CDK4/6 inhibitor drugs to maximize the therapeutic potential and effectiveness of ARV-471 in treating this challenging medical condition.

Major companies operating in the cyclin-dependent kinase (cdk) 4/6 inhibitor drugs market report are Pfizer Inc., Merck & Co. Inc., Novartis AG, Bristol Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc, Incyte Corporation, Jiangsu Hengrui Pharmaceuticals Co. Ltd., Dr. Reddy’s Laboratories Ltd, Piramal Group, Hanmi Pharm Co. Ltd., Incepta Pharmaceuticals Ltd, Beacon Pharmaceuticals PLC, Bluepharma, Astex Pharmaceuticals, Arvinas Inc , G1 Therapeutics Inc., Carisma Therapeutics Inc., Beta Pharma Inc., Syros Pharmaceuticals Inc., Cyclacel Pharmaceuticals Inc., Onconova Therapeutics Inc., Context Therapeutics Inc., NanoDaru.

North America was the largest region in the cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market in 2023. The regions covered in the cyclin-dependent kinase (cdk) 4/6 inhibitor drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the cyclin-dependent kinase (cdk) 4/6 inhibitor drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cyclin-dependent kinase (CDK) 4/6 inhibitor drug market consists of sales of trilaciclib and ramiven drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The primary CDK 4/6 inhibitor drugs include palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio). Palbociclib, for instance, is a targeted therapy medication designed for treating hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer. It is often utilized in combination with endocrine therapy, offering an effective treatment option for patients with advanced or metastatic breast cancer. These drugs cater to various patient groups, such as premenopausal, postmenopausal, and others. The end users encompass hospitals, clinics, research laboratories, and retail pharmacies.

The cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market research report is one of a series of new reports that provides cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market statistics, including cyclin-dependent kinase (CDK) 4/6 inhibitor drugs industry global market size, regional shares, competitors with a cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market share, detailed cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market segments, market trends and opportunities, and any further data you may need to thrive in the cyclin-dependent kinase (CDK) 4/6 inhibitor drugs industry. This cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future- scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Characteristics3. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Trends and Strategies
4. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market - Macro Economic Scenario
4.1. Impact of High Inflation on the Market
4.2. Ukraine-Russia War Impact on the Market
4.3. COVID-19 Impact on the Market
5. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Size and Growth
5.1. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Drivers and Restraints
5.1.1. Drivers of the Market
5.1.2. Restraints of the Market
5.2. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Historic Market Size and Growth, 2018-2023, Value ($ Billion)
5.3. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Forecast Market Size and Growth, 2023-2028, 2033F, Value ($ Billion)
6. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Segmentation
6.1. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Palbociclib (Ibrance)
  • Ribociclib (Kisqali)
  • Abermaciclib (Verzenio)
6.2. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Pre-Menopausal
  • Post-Menopausal
  • Other Patients
6.3. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Clinics
  • Research Laboratories
  • Retail Pharmacies
7. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Regional and Country Analysis
7.1. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Split by Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Split by Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market
8.1. Asia-Pacific Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
Region Information, Impact of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market
9.1. China Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
9.2. China Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market
10.1. India Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market
11.1. Japan Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
11.2. Japan Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market
12.1. Australia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market
13.1. Indonesia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market
14.1. South Korea Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
14.2. South Korea Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market
15.1. Western Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
15.2. Western Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market
16.1. UK Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market
17.1. Germany Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market
18.5. France Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.6. France Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.7. France Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market
19.9. Italy Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.10. Italy Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.11. Italy Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market
20.13. Spain Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.14. Spain Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.15. Spain Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market
21.1. Eastern Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
21.2. Eastern Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market
22.1. Russia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market
23.1. North America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
23.2. North America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market
24.1. USA Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
24.2. USA Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market
25.1. Canada Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
25.2. Canada Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market
26.1. South America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
26.2. South America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market
27.1. Brazil Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market
28.1. Middle East Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
28.2. Middle East Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market
29.1. Africa Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
29.2. Africa Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Competitive Landscape and Company Profiles
30.1. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Competitive Landscape
30.2. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Company Profiles
30.2.1. Pfizer Inc.
30.2.1.1. Overview
30.2.1.2. Products and Services
30.2.1.3. Strategy
30.2.1.4. Financial Performance
30.2.2. Merck & Co. Inc.
30.2.2.1. Overview
30.2.2.2. Products and Services
30.2.2.3. Strategy
30.2.2.4. Financial Performance
30.2.3. Novartis AG
30.2.3.1. Overview
30.2.3.2. Products and Services
30.2.3.3. Strategy
30.2.3.4. Financial Performance
30.2.4. Bristol Myers Squibb Company
30.2.4.1. Overview
30.2.4.2. Products and Services
30.2.4.3. Strategy
30.2.4.4. Financial Performance
30.2.5. AstraZeneca PLC
30.2.5.1. Overview
30.2.5.2. Products and Services
30.2.5.3. Strategy
30.2.5.4. Financial Performance
31. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Other Major and Innovative Companies
31.1. Eli Lilly and Company
31.2. Boehringer Ingelheim International GmbH
31.3. Gilead Sciences, Inc
31.4. Incyte Corporation
31.5. Jiangsu Hengrui Pharmaceuticals Co. Ltd.
31.6. Dr. Reddy’s Laboratories Ltd
31.7. Piramal Group
31.8. Hanmi Pharm Co. Ltd.
31.9. Incepta Pharmaceuticals Ltd
31.10. Beacon Pharmaceuticals PLC
31.11. Bluepharma
31.12. Astex Pharmaceuticals
31.13. Arvinas Inc
31.14. G1 Therapeutics Inc.
31.15. Carisma Therapeutics Inc.
32. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Competitive Benchmarking33. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Competitive Dashboard34. Key Mergers and Acquisitions in the Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market
35. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Future Outlook and Potential Analysis
35.1 Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market in 2028 - Countries Offering Most New Opportunities
35.2 Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market in 2028 - Segments Offering Most New Opportunities
35.3 Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market in 2028 - Growth Strategies
35.3.1 Market Trend-based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic and Forecast Inflation Rates
36.4. Research Inquiries
36.5. About the Analyst
36.6. Copyright and Disclaimer

Executive Summary

Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Description

Where is the largest and fastest growing market for cyclin-dependent kinase (CDK) 4/6 inhibitor drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
  • The impact of higher inflation in many countries and the resulting spike in interest rates.
  • The continued but declining impact of COVID-19 on supply chains and consumption patterns.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:
1) By Drug Type: Palbociclib (Ibrance); Ribociclib (Kisqali); Abermaciclib (Verzenio)
3) By Patient: Pre-Menopausal; Post-Menopausal; Other Patients
3) By End-Users: Hospitals; Clinics; Research Laboratories; Retail Pharmacies

Key Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Novartis AG; Bristol Myers Squibb Company; AstraZeneca PLC

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes

Delivery Format: PDF, Word and Excel Data Dashboard

Methodology

Loading
LOADING...